Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs

Perrotta, Fabio Massimo; Marchesoni, Antonio; Lubrano, Ennio

doi:10.3899/jrheum.150805

Cited by 72 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our recent prospective study 5 we found that about 60% of 75 patients with PsA treated with anti-tumor necrosis factor agents reached the classic MDA (5/7) criteria after 12 months of therapy. The work by Coates and Helliwell prompted us to review our data and we found, as expected, that a lower rate (37.3%) of our 75 patients reached an MDA 7/7 criteria after 12 months of therapy, with a similar rate (56%) of patients reaching the MDA-joints (Figure 1).…”

Section: To the Editormentioning

confidence: 90%

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments

Lubrano

Perrotta

2016

J Rheumatol

Self Cite

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 90%

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments

Lubrano

Perrotta

2016

J Rheumatol

Self Cite

View full text Add to dashboard Cite

“…The relationship between a low HAQ score at baseline and an increased likelihood of achieving MDA has been substantiated in a clinical trial setting with both golimumab (GOL) 17 and adalimumab 34 , with evidence from the Adalimumab Effectiveness in Psoriatic Arthritis trial (ADEPT) also supporting the correlation between low baseline enthesitis and achievement of MDA. It remains unclear whether inflammatory burden, as measured by erythrocyte sedimentation rate and C-reactive protein (CRP), is a predictor of achieving MDA 27,30,32 .…”

Section: Predictors Of Achieving Mdamentioning

confidence: 99%

“…A number of real-world clinical studies have assessed MDA in patients with PsA (Table 2) 26,27,28,29,30 . In these observational and open-label cohorts, the proportion of patients treated with TNF inhibitors meeting MDA criteria at least once in 12 months ranged from 44% to 64%.…”

Section: Frequency Of Mda In Observational Studiesmentioning

confidence: 99%

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature

et al. 2017

Self Cite

View full text Add to dashboard Cite

As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire. Since its development, MDA has been used increasingly in studies and clinical trials. In this article, the potential use of MDA as a treatment target in PsA is reviewed. The frequencies of MDA achievement with biologic disease-modifying antirheumatic drugs are summarized based on data from registries, observational studies, and clinical trials. Predictors and the prognostic effect of attaining MDA are also evaluated.

show abstract

“…n CONCLUSIONS Anti-TNF therapy showed its efficacy and safety in different rheumatic diseases and now a state of remission or low disease activity are achievable targets even in spondyloarthritis in general (42,43) and in PsA (44)(45)(46). However, about 40% of patients lack to respond to TNF inhibitors.…”

Section: Apremilastmentioning

confidence: 99%

New approved drugs for psoriatic arthritis

Perrotta

Lubrano

2016

Reumatismo

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage and to a reduction of joint function and poor quality of life. Treatment of PsA has changed since its introduction of anti- TNF drugs, which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. However, recently, the discovery of new pathogenic mechanisms have made possible the development of new molecules that target pro-inflammatory cytokines involved in skin, joint and entheseal inflammation. New drugs like ustekinumab, secukinumab and apremilast inhibit interleukin axis and intracellular pathways and showed their efficacy and safety in randomized clinical trials. These drugs have been recently approved for the treatment of PsA and included in the new EULAR and GRAPPA treatment recommendations. The aim of this paper is to briefly review the clinical trials that led to their approval for PsA.

show abstract

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs

Abstract: In our prospective observational study, based on a clinical practice setting, MDA was achieved in 61.3% of patients treated with TNF-α blockers, identifying this as an achievable target for patients with PsA. Predictors of remission were also identified.

Cited by 72 publications

References 29 publications

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature

New approved drugs for psoriatic arthritis

Contact Info

Product

Resources

About